Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,373 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05618041Recruiting
CAR-T treatment trial for relapsed or hard-to-treat blood cancers
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Taiyuan, ShanxiAges 14–75 - NCT05631886RecruitingPhase 1
Testing a cancer vaccine plus immune therapy for hard tumors
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
Beijing, Beijing MunicipalityAges 18–75 - NCT05641428RecruitingPhase 2
Testing a made-at-bedside CAR T cell for relapsed lymphoma
This Phase 2 study compares a “point-of-care” CAR T-cell treatment made at the hospital right away versus standard commercial CAR T-cells. It’s for adults with relapsed or refractory large B-cell lymphoma (a type of blood cancer) to see which approach works best and is safe.
AmsterdamAges 18 years+ - NCT05643235Recruiting
Loop monitor to watch heart rhythms when starting a BTK inhibitor
This study checks how often abnormal heart rhythms happen when you start a BTK inhibitor (used for certain blood cancers). It uses a small implanted heart monitor to record your rhythm continuously before and after starting the medication, so doctors can detect and manage problems early.
New Hyde Park, New YorkAges 18 years+ - NCT05646576Recruiting
Palliative care support during blood cancer cell therapy
This trial studies whether adding palliative care (comfort-focused care to reduce stress and symptoms) helps people during adoptive cell therapy for blood cancers. It may help improve quality of life while you’re receiving the therapy.
Boston, MassachusettsAges 18 years+ - NCT05654675Recruiting
Scan method study for measuring tumor sugar use on PET
This study checks whether a specific analysis method (called FUR) can better measure how much “sugar” from PET scans is used by tumors. It uses regular PET/CT scans you may already get as part of standard care, and compares how the measurements work.
Maastricht, LimburgAges 18 years+ - NCT05659628RecruitingPhase 1
CD19 CAR-T plus PD-1 antibody for relapsed lymphoma
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
Hangzhou, ZhejiangAges 18–75 - NCT05659732RecruitingPhase 1
Testing a new drug for advanced blood cancers
This early-phase study tests PEP07, a drug that blocks a cancer signal pathway (Checkpoint Kinase 1). It aims to see how well it works and how safely it can be given to people with certain advanced relapsed or refractory blood cancers.
Clayton, VictoriaAges 18 years+ - NCT05660473RecruitingPhase 2
Study of venetoclax plus chemotherapy for Ph-negative ALL
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
TianjinAges 14–60 - NCT05674175RecruitingPhase 1/Phase 2
Test two engineered immune cell treatments for B-cell leukemia
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
Philadelphia, PennsylvaniaAges Up to 29 years - NCT05675813RecruitingPhase 1/Phase 2
Genetic test-guided treatment for newly diagnosed peripheral T-cell lymphoma
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05679895RecruitingPhase 1
Study drug OC-1 for CD1a-positive T-ALL or T-LL after relapse
This Phase 1 trial tests the safety and early signs of benefit of OC-1 in people with relapsed or hard-to-treat T-cell leukemia/lymphoma (T-ALL/LL) that has a CD1a marker. You may be considered if standard treatments didn’t work or the cancer returned, and if your organs and infections are controlled.
BarcelonaAges 2 years+ - NCT05680558RecruitingPhase 2
Photopheresis for early skin lymphoma in adults
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
New York, New YorkAges 18 years+ - NCT05694312RecruitingPhase 2
Ibrutinib for anemia caused by immune destruction in CLL/SLL
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
FlorenceAges 18 years+ - NCT05702853RecruitingPhase 1/Phase 2
CAR T-cell therapy after CD34 selection for CD19 lymphoma or CLL
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
Charleston, South CarolinaAges 18 years+ - NCT05724121Recruiting
Study heart rhythm changes during BTK or venetoclax treatment
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
Bethesda, MarylandAges 18–110 - NCT05757219RecruitingPhase 2
Itacitinib before CAR T for aggressive B-cell lymphoma
This trial tests itacitinib given before CAR T cell therapy to see if it can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). It may help by calming certain immune signals before CAR T is started.
Tampa, FloridaAges 18 years+ - NCT05779605Recruiting
Online rehab for lymphoma survivors after chemotherapy
This trial tests a telerehabilitation (remote exercise/rehab) program for people with recent lymphoma or other blood cancers after chemotherapy. It aims to improve recovery and fitness while monitoring safety through an exercise test and check-ins.
BrnoAges 18 years+ - NCT05806099RecruitingPhase 1/Phase 2
Study of MBS303 for CD20-positive B-cell lymphoma that returned
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
BeijingAges 18 years+ - NCT05809180Recruiting
Tested chemo regimen for newly diagnosed older adults with DLBCL
This study tests a “mini-CHOP-like” chemotherapy plan for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in people age 70 and older. It may help you learn whether this gentler regimen works well and is safe in older adults who are newly starting treatment.
Suzhou, JiangsuAges 70 years+ - NCT05831865Recruiting
Testing best first-line stem cell transplant for aggressive lymphoma
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Beijing, Beijing MunicipalityAges 18–70 - NCT05909059RecruitingPhase 2
CAR-T therapy for people with kidney function problems
This study tests a type of immune treatment (CAR-T) in people whose kidneys are not working well, using chemotherapy first to help the CAR-T work. It may help people with certain blood cancers who have reduced kidney function to still receive CAR-T therapy safely.
Atlanta, GeorgiaAges 18 years+ - NCT05858424Recruiting
Day hospital program to improve young cancer survivors’ well-being
This study tests a structured “end-of-treatment” day hospital program to improve quality of life for adolescents and young adults after cancer treatment. You may be offered follow-up and supportive care soon after finishing treatment to help you feel better physically and emotionally.
LyonAges 15–25 - NCT05880043RecruitingPhase 1/Phase 2
IV NK cell treatment for advanced cancers that returned
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
SeoulAges 19 years+
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,373 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.